-
Beijing Aosaikang Pharmaceuticals Boosts Stake in US Subsidiary AskGene with RMB 220 Million Investment
•
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced a capital injection of RMB 220 million (USD 31 million) into its US-based subsidiary, AskGene Limited, established in 2012. This investment increases the Chinese firm’s shareholding in AskGene from 59.07% to 62.86%, solidifying its position as the controlling shareholder. Concurrently, TF…
-
Beijing Aosaikang Pharmaceuticals Achieves Clinical Milestone for c-MET Inhibitor ASKC202
•
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced the presentation of promising data from a Phase I dosage escalation study (ASKC202-001) for its investigational small-molecule c-MET inhibitor, ASKC202, in advanced solid tumors at the American Association for Cancer Research (AACR) 2024 annual meeting. This development underscores the company’s commitment…
-
Aosaikang’s Marketing Approval Filing for Delafloxacin Accepted by China’s NMPA
•
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755), a Chinese pharmaceutical company, has announced that the National Medical Product Administration (NMPA) in China has accepted for review its marketing approval filing for the Category III chemical injectable drug delafloxacin. Delafloxacin is a new generation broad-spectrum fluoroquinolone antibiotic indicated for the treatment…
-
Beijing Aosaikang Initiates Phase III Trial for Advanced Gastric Cancer Treatment
•
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755), a Chinese pharmaceutical company, has registered a Phase III clinical study with Clinicaltrials.gov for its Claudin18.2-targeted antibody ASKB589. The trial will investigate the use of ASKB589 in combination with tislelizumab and chemotherapy as a first-line treatment for advanced gastric cancer. The study aims…
-
Beijing Aosaikang’s Combo Therapy for NSCLC Accepted for Clinical Trial by NMPA
•
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755), a Chinese pharmaceutical company, has announced that the China National Medical Products Administration (NMPA) has accepted a clinical trial application for the combination of two pipeline candidates, ASKC202 tablets and ASK120067 tablets. The company is seeking to evaluate this combination therapy in adults…
